loading

Brainstorm Cell Therapeutics Inc 주식(BCLI)의 최신 뉴스

pulisher
Jul 25, 2025

What analysts say about Brainstorm Cell Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Brainstorm Cell Therapeutics Inc. stock priceRapid capital growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What risks could impact Brainstorm Cell Therapeutics Inc. stock performanceMarket-beating performance - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Is Brainstorm Cell Therapeutics Inc. a good long term investmentFree Stock Selection - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

How Brainstorm Cell Therapeutics Inc. stock reacts to Fed policy changesAccelerated financial growth - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

BrainStorm Cell Therapeutics Downgraded to Hold by Maxim Group - AInvest

Jul 24, 2025
pulisher
Jul 23, 2025

Maxim Group Downgrades Brainstorm Cell Therapeutics(BCLI.US) to Hold Rating, Raises Target Price to $6.6 - 富途牛牛

Jul 23, 2025
pulisher
Jul 22, 2025

Brainstorm Cell Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' - Stocktwits

Jul 18, 2025
pulisher
Jul 18, 2025

Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - inkl

Jul 18, 2025
pulisher
Jul 17, 2025

Brainstorm Cell Therapeutics Announces Nasdaq Delisting And Transition To Otcqb - TradingView

Jul 17, 2025
pulisher
Jul 17, 2025

Brainstorm Cell Therapeutics Faces Nasdaq Delisting Notice - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Brainstorm Cell Therapeutics to Delist From Nasdaq - MarketScreener

Jul 17, 2025
pulisher
Jul 17, 2025

BrainStorm Cell Therapeutics shares fall 51.20% after-hours after Nasdaq delisting notification. - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

BrainStorm Cell Therapeutics stock delisted from Nasdaq, trades on OTCQB - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB By Investing.com - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB - WV News

Jul 17, 2025
pulisher
Jul 17, 2025

BrainStorm Receives 3 Million NIS Grant from Israel's Office of the Chief Scientist - AOL.com

Jul 17, 2025
pulisher
Jul 15, 2025

Why Brainstorm Cell Therapeutics Inc. stock attracts strong analyst attentionFree Deep Market Trend Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Brainstorm Cell Therapeutics Inc. stock price move sharplyFree Stock Trading Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Brainstorm Cell Therapeutics Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data - BioSpace

Jul 08, 2025
pulisher
Jul 08, 2025

BTCS, BrainStorm Cell, Moderna - TradingView

Jul 08, 2025
pulisher
Jul 08, 2025

FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness - The Malaysian Reserve

Jul 08, 2025
pulisher
Jul 08, 2025

BrainStorm Cell Therapeutics: A Rare Disease Breakthrough on the Brink of Regulatory Approval - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

NurOwn's Regulatory Crossroads: Why BrainStorm Cell Therapeutics (BCLI) Could Be Poised for a Turnaround - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn - Investing.com

Jul 08, 2025
pulisher
Jul 07, 2025

BCLI: Citizen's Petition Filed Requesting the FDA Approve NurOwn - Smartkarma

Jul 07, 2025
pulisher
Jul 07, 2025

ALS Community Files Citizens’ Petition asking FDA to Approve NurOwn Stem Cell Therapy - Asbury Park Press

Jul 07, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):